3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Neoplasms
4
Leukemia, B-Cell
3
Recurrence
2
Leukemia
2
Bronchiolitis Obliterans Syndrome
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
ofatumumab
×
Clear all
NCT01578707
2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3
Completed
391 enrolled
14 charts
NCT01014208
2015-08-07
ORCHARRD
GlaxoSmithKline
Phase 3
Completed
447 enrolled
21 charts